<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">32107781</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1365-2133</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>182</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>The British journal of dermatology</Title>
          <ISOAbbreviation>Br J Dermatol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Pachyonychia congenita, a paradigm for rare skin disorders.</ArticleTitle>
        <Pagination>
          <StartPage>521</StartPage>
          <EndPage>522</EndPage>
          <MedlinePgn>521-522</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/bjd.18817</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Steele</LastName>
            <ForeName>L</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Centre for Cell Biology and Cutaneous Research, Blizard Institute, Queen Mary University of London and Department of Dermatology, Barts Health NHS Trust, London, ERN-Skin, U.K.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>O'Toole</LastName>
            <ForeName>E A</ForeName>
            <Initials>EA</Initials>
            <Identifier Source="ORCID">0000-0002-4084-4836</Identifier>
            <AffiliationInfo>
              <Affiliation>Centre for Cell Biology and Cutaneous Research, Blizard Institute, Queen Mary University of London and Department of Dermatology, Barts Health NHS Trust, London, ERN-Skin, U.K.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016421">Editorial</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Br J Dermatol</MedlineTA>
        <NlmUniqueID>0004041</NlmUniqueID>
        <ISSNLinking>0007-0963</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053549" MajorTopicYN="Y">Pachyonychia Congenita</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D035583" MajorTopicYN="N">Rare Diseases</DescriptorName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012867" MajorTopicYN="N">Skin</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012871" MajorTopicYN="Y">Skin Diseases</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32107781</ArticleId>
        <ArticleId IdType="doi">10.1111/bjd.18817</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References</Title>
        <Reference>
          <Citation>EURORDIS (European Organisation for Rare Diseases). Rare diseases: Understanding this Public Health Priority. Available at: https://www.eurordis.org/IMG/pdf/princeps_document-EN.pdf (last accessed 18 Dec 2019).</Citation>
        </Reference>
        <Reference>
          <Citation>Department of Health. The UK Strategy for Rare Disease. Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/260562/UK_Strategy_for_Rare_Diseases.pdf (last accessed 18 Dec 2019).</Citation>
        </Reference>
        <Reference>
          <Citation>Hedley V, Murray H, Rodwell C et al. Report on the State of the Art of Rare Disease Activities in Europe. 2018 version. Available at: http://www.rd-action.eu/wp-content/uploads/2018/09/Final-Overview-Report-State-of-the-Art-2018-version.pdf (last accessed 18 Dec 2019).</Citation>
        </Reference>
        <Reference>
          <Citation>Rath A, Salamon V, Peixoto S et al. A systematic literature review of evidence-based clinical practice for rare diseases: what are the perceived and real barriers for improving the evidence and how can they be overcome? Trials 2017; 18:556.</Citation>
        </Reference>
        <Reference>
          <Citation>Soon K, Mason R, Martinez AE, Mellerio JE. The psychological functioning of children with epidermolysis bullosa and its relationship with specific aspects of disease. Br J Dermatol 2020; 182:789-90.</Citation>
        </Reference>
        <Reference>
          <Citation>Simpson JK, Martinez-Queipo M, Onoufriadis A et al. Genotype-phenotype correlation in a large English cohort of patients with autosomal recessive ichthyosis. Br J Dermatol 2020; 182:729-37.</Citation>
        </Reference>
        <Reference>
          <Citation>Angwin C, Ghali N, Baker D et al. Electron microscopy in the diagnosis of Ehlers-Danlos syndromes: correlation with clinical and genetic investigations. Br J Dermatol 2020; 182:698-707.</Citation>
        </Reference>
        <Reference>
          <Citation>Forrest CB, Bartek RJ, Rubinstein Y, Groft SC. The case for a global rare-diseases registry. Lancet 2011; 377:1057-9.</Citation>
        </Reference>
        <Reference>
          <Citation>Samuelov L, Smith FJD, Hansen CD, Sprecher E. Revisiting pachyonychia congenita: a case-cohort study of 815 patients. Br J Dermatol 2020; 182:738-46.</Citation>
        </Reference>
        <Reference>
          <Citation>Weinberg RL, Coulombe PA, Polydefkis M, Caterina MJ. Pain mechanisms in hereditary palmoplantar keratodermas. Br J Dermatol 2020; 182:543-51.</Citation>
        </Reference>
        <Reference>
          <Citation>Koren A, Sprecher E, Reider E, Artzi O. A treatment protocol for botulinum toxin injections in the treatment of pachyonychia congenita-associated keratoderma. Br J Dermatol 2020; 182:671-77.</Citation>
        </Reference>
        <Reference>
          <Citation>Hickerson RP, Leake D, Pho LN et al. Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients. J Dermatol Sci 2009; 56:82-8.</Citation>
        </Reference>
        <Reference>
          <Citation>Abdollahimajd F, Rajabi F, Shahidi-Dadras M et al. Pachyonychia congenita: a case report of a successful treatment with rosuvastatin in a patient with a KRT6A mutation. Br J Dermatol 2019; 181:584-6.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhao Y, Gartner U, Smith FJ, McLean WH. Statins downregulate K6a promoter activity: a possible therapeutic avenue for pachyonychia congenita. J Invest Dermatol 2011; 131:1045-52.</Citation>
        </Reference>
        <Reference>
          <Citation>Funk T, Hansen CD, Paller A, O'Toole EA. Update on pachyonychia congenita research. Br J Dermatol 2020; 182:788-89.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
